|
Female and/or Male subjects of any race, in good general health, aged 18-65 years old, inclusive at enrollment |
|
|
|
|
Individuals who are able to cooperate with the Principal Investigator and study personnel throughout the duration of the study and are willing to comply with all study procedures, methods, evaluations, and study product use |
|
|
|
|
Individuals who are able to read, understand and willing to sign an informed consent for this specific study and have completed all site required documentation prior to study enrollment (Registration and Medical History) |
|
|
|
|
Individuals willing to be photographed and sign a model release |
|
|
|
|
Individuals with mild to moderate acne (minimum of 3 lesions, at least 1 inflammatory) |
|
|
|
|
Individuals who are currently using prescription (topical or oral) acne medications
|
|
|
|
|
Individuals who are using over the counter acne treatment products
|
|
|
|
|
Individuals with acute or chronic disease(s) or medical condition(s), including dermatological problems, which could put them at risk in the opinion of the Principal Investigator or compromise the study outcome. Typical uncontrolled chronic or serious diseases and conditions which would prevent participation in any clinical study are cancer, AIDS, insulin-dependent diabetes, renal impairment, mental illness, and/or drug/alcohol addiction
|
|
|
|
|
Individuals with a history of melanoma, or a treated skin cancer within the last 5 years
|
|
|
|
|
Individuals who are pregnant, lactating, or planning to become pregnant. Individuals who become pregnant during the study must inform the Principal Investigator immediately
|
|
|
|
|
Individuals who are unreliable or unlikely to be available for the duration of the study
|
|
|
|
|
Individuals with a history of allergic reactions, skin sensitization and/or known allergies to cosmetic and personal care products/ingredients
|
|
|
|
|
Individuals who are immunocompromised
|
|
|
|
|
Individuals who are employees of VCS or other testing firms/laboratories, cosmetic or raw goods manufacturers or suppliers
|
|
|
|
|
Individuals who are unable to communicate or cooperate with the Principal Investigator/study personnel due to language problems, poor mental development, or impaired cerebral function
|
|
|
|
|
Individuals who started Hormone Replacement Therapy within the last three months preceding the commencement of the study
|
|
|
|
|
Individuals who are using oral contraception for less than three months before study commencement or who have changed their contraceptive method within the three months before the Baseline visit or planning to modify their contraception treatment within the duration of the study
|
|
|
|
|
Individuals who have traveled (domestically or internationally) 5 days prior to any visit throughout the study
|
|
|
|
|
Individuals with COVID-19 related symptoms, per CDC, within 48 hours prior to any visit throughout the study
|
|
|
|
|
Individuals who have used a fever reducer within 12 hours prior to any site visit
|
|
|
|